Supplier News Breaks Archives
GlaxoSmithKline releases COPD treatment to pharmacies
April 29th, 2014
RESEARCH TRIANGLE PARK, N.C. – GlaxoSmithKline plc and Theravance Inc. have rolled out Anoro Ellipta, an inhaler for the treatment of chronic obstructive pulmonary disease (COPD), to retail pharmacies in the United States.
GSK said Monday that Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is the first once-daily product approved in the United States that combines two long-acting bronchodilators in one inhaler for the maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
"We understand that COPD is a progressive disease affecting an estimated 27 million people in the US alone," stated Jorge Bartolome, senior vice president of the GSK respiratory business unit in the United States. "Anoro Ellipta is an important treatment option for appropriate patients with COPD, and we are proud to make it available in the U.S."
According to the National Heart, Lung and Blood Institute (NHLBI), long-term exposure to lung irritants that damage the lungs and the airways are typically the cause of COPD. In the United States, the most common irritant that causes COPD is cigarette smoke. Breathing in secondhand smoke, air pollution, chemical fumes or dust from the environment or workplace also can contribute to COPD. Most people who have COPD are at least 40 years old when symptoms begin.
"We are very pleased that Anoro Ellipta, the latest combination medicine to be developed as a result of our partnership with GSK, is now available in the U.S.," commented Rick Winningham, chief executive officer of Theravance. "We believe this product will add to the choice of treatment options available to physicians when considering how to help meet the needs of their patients."